RCT: Tofacitinib (oral drug) is an effective treatment in patients with polyarticular course juvenile idiopathic arthritis.

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

NEW in @TheLancet — Tofacitinib in juvenile idiopathic #arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

Flare rate by week 44 was significantly lower with tofacitinib (29%) than with placebo (53%) https://t.co/28JRrbPf8e #JIA pic.twitter.com/JzxHLNmgym

— The Lancet Rheumatology (@TheLancetRheum) November 10, 2021